Skip to main content
TipRanks
Go Ultimate75% OFF

EPS Creative Health Technology Group Limited (3860) AI Stock Analysis

0 Followers
HK:3860

EPS Creative Health Technology Group Limited

(HKEX:3860)

Select Model
Rating:43Neutral
Price Target:HKD 0.63â–¼(-3.54% Downside)
Action:reiterated
Date:08/29/26

The overall score is constrained by unstable earnings and cash flows, including repeated losses and a recent swing back into the red, partially offset by a significantly de-levered balance sheet and a return to positive operating and free cash flow, while weak price action below key moving averages and a loss-driven, unappealing P/E keep the assessment in the lower range.

Positive Factors
Lower leverageMaterial debt reduction lowers balance-sheet risk and should reduce pressure from financing obligations. The resulting low debt-to-equity position gives the company greater flexibility to withstand operating volatility and allocate resources toward maintaining or rebuilding the business.
Negative Factors
Volatile revenueThe uneven revenue pattern makes near-term planning and earnings forecasting less reliable. A modest rebound after a meaningful decline does not yet demonstrate durable demand momentum, potentially limiting operating leverage and the company’s ability to build consistent profitability.

EPS Creative Health Technology Group Limited (3860) vs. iShares MSCI Hong Kong ETF (EWH)

-30%-20%-10%0%10%20%HK:3860-1.52%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 378.58M
Dividend Yield
1.54%
Average Volume (3M)
287.17K
Price to Earnings (P/E)
-24.5
Beta (1Y)
0.24
Revenue Growth
-15.95%
EPS Growth
-135.81%
Country
Hong Kong
Employees
133
Sector
Consumer Cyclical
Sector Strength
61
Industry
Apparel - Retail

EPS Creative Health Technology Group Limited Business Overview & Revenue Model

Company Description

EPS Creative Health Technology Group Limited functions as an investment holding company with diverse operations. It specializes in comprehensive apparel supply chain management, serving clients across Hong Kong, mainland China, Japan, the United Stat...

How the Company Makes Money

null

EPS Creative Health Technology Group Limited Financial Statement Overview

Summary

Volatile profitability with repeated loss-making years and a sharp swing from a solid profit in 2025 to a loss in 2026 weighs heavily on the score, despite a now low-leverage balance sheet and a recent return to positive operating and free cash flow.

Income Statement

32Negative

Balance Sheet

58Neutral

Cash Flow

45Neutral
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue457.65M457.65M544.52M644.62M452.91M519.95M
Gross Profit75.02M75.02M94.58M99.26M67.85M76.78M
EBITDA17.63M17.63M57.53M-2.96M-37.88M-14.53M
Net Income-13.85M-13.85M38.59M-22.07M-45.74M-22.60M
Balance Sheet
Total Assets311.39M311.39M336.85M429.88M227.49M248.92M
Cash, Cash Equivalents and Short-Term Investments130.49M130.49M135.69M131.51M131.47M208.14M
Total Debt4.45M4.45M57.22M11.45M73.61M9.14M
Total Liabilities158.67M158.67M174.33M291.70M135.85M122.22M
Stockholders Equity105.91M105.91M120.68M65.36M87.64M131.32M
Cash Flow
Free Cash Flow25.11M25.11M-23.63M-33.60M-40.52M9.99M
Operating Cash Flow28.21M28.21M-17.92M-28.57M-38.11M10.05M
Investing Cash Flow-3.09M-2.98M57.20M-20.40M-11.38M4.57M
Financing Cash Flow-32.76M-37.51M-16.78M33.66M-27.75M98.11M

EPS Creative Health Technology Group Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price0.65

Price Trends

50DMA0.60Positive
100DMA0.59Positive
200DMA0.60Positive

Market Momentum

MACD0.01Negative
RSI66.90Neutral
STOCH95.06Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3860, the sentiment is Positive. The current price of 0.65 is above the 20-day moving average (MA) of 0.60, above the 50-day MA of 0.60, and above the 200-day MA of 0.60, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 66.90 is Neutral, neither overbought nor oversold. The STOCH value of 95.06 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3860.

EPS Creative Health Technology Group Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

HK:3860 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:1368HK:136874OutperformHKD 9.71B6.5112.21%7.64%10.47%-8.83%
HK:3709HK:370972OutperformHKD 3.36B7.188.44%7.14%-4.39%-12.10%
HK:6288HK:628871OutperformHKD 1.27T47.6820.26%1.06%11.14%19.43%
HK:0709HK:070968NeutralHKD 1.94B9.5210.15%10.92%-2.94%-6.03%
HK:6110HK:611066NeutralHKD 6.82B5.3513.22%28.32%-3.43%-0.67%
Sector *61Neutral$18.38B12.79-2.54%3.03%1.52%-15.83%
HK:3860HK:386043NeutralHKD 378.58M-24.53-12.65%1.54%-15.95%-135.81%

* Consumer Cyclical Sector Average

Performance Comparison

-50%0%50%HK:3860HK:0709HK:1368HK:3709HK:6110HK:6288Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:3860 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:3860EPS Creative Health Technology Group Limited0.65-0.05-7.14%
HK:0709Giordano International 1.20-0.18-12.79%
HK:1368Xtep International Holdings 3.60-1.93-34.90%
HK:3709EEKA Fashion Holdings Limited4.90-3.09-38.65%
HK:6110Topsports International Holdings Limited1.10-1.71-60.83%
HK:6288Fast Retailing Co Ltd Shs Unsponsored Hong Kong Depositary Receipt Repr 1/100th Sh39.6013.1449.66%

EPS Creative Health Technology Group Limited Corporate Events

EPS Creative Updates Expected Six-Month Loss Range

Nov 16, 2026

EPS Creative Health Technology Group Limited, incorporated in the Cayman Islands, issued a supplemental update to its profit warning covering the six months ended 30 September 2026. The release does not specify the Group’s industry or primary product...

EPS Creative Announces Broad Board and Management Changes

Nov 2, 2026

EPS Creative Health Technology Group Limited announced broad leadership changes effective 2 November 2026. Washikita Kenichiro will remain chairman and an executive director after stepping down as chief executive, while Miyano Tsumoru, Narumi Shoichi...

EPS Creative Health Technology Group Announces Board and Committee Structure

Nov 2, 2026

EPS Creative Health Technology Group Limited announced its board composition, comprising seven executive directors, one non-executive director and four independent non-executive directors. The company also disclosed membership of its Audit, Remunerat...

EPS Creative Health Technology Faces Governance Gap After Independent Director Resigns

Oct 9, 2026

EPS Creative Health Technology Group Limited announced the resignation of independent non-executive director Mr. Choi Koon Ming, effective 9 October 2026, as he seeks to focus on other business commitments. His departure also ends his roles as chairm...

EPS Creative Health Technology Updates Board and Committee Structure

Oct 9, 2026

EPS Creative Health Technology Group Limited has detailed the composition of its board of directors, naming six executive directors, one non-executive director and three independent non-executive directors. The leadership team spans core functions su...

EPS Creative Health Issues Profit Warning on Rising Losses and Margin Pressure

Oct 2, 2026

EPS Creative Health Technology Group Limited has warned that it expects a higher loss after tax of about HK$8 million to HK$12 million for the six months ended 30 September 2026, compared with the same period a year earlier. The board attributes this...

EPS Creative Health Tech’s Controlling Shareholder to Sell 22% Stake While Retaining Control

Sep 9, 2026

EPS Creative Health Technology Group Limited has announced that controlling shareholder EPS Holdings, Inc. has agreed to sell up to 130 million shares, or 22.32% of the company’s issued share capital, to Hong Kong‑based Wisdoms Group International at...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 29, 2026